Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VAFSEO vs EPOGEN/PROCRIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
Treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis,Treatment of anemia due to zidovudine in HIV-infected patients,Treatment of anemia due to myelosuppressive chemotherapy in patients with non-myeloid malignancies,Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Oral: 20 mg three times weekly for 24 weeks.
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/d L).
Terminal half-life is approximately 20-30 hours, supporting once-daily dosing.
Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance).
Primarily metabolized by CYP2C8 and UGT1A9; minor pathways include CYP3A4 and CYP2C9.
Metabolized by proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily fecal (approximately 81%) and renal (~17%) as unchanged drug and metabolites.
Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible.
~50% bound to plasma proteins, primarily albumin.
Approximately 50% bound to serum proteins; no specific binding protein identified.
Apparent volume of distribution is approximately 1.5 L/kg, indicating extensive extravascular distribution.
Vd = 0.03–0.06 L/kg, approximating plasma volume; indicates limited extravascular distribution.
Oral bioavailability is approximately 60-70% (not affected by food).
Subcutaneous: ~20-30% compared to IV.
No dosage adjustment required for any degree of renal impairment.
No standard GFR-based adjustment for epoetin alfa; dosing is based on hemoglobin response. In chronic kidney disease, initiate when hemoglobin <10 g/d L; titrate to avoid hemoglobin >11 g/d L.
No dosage adjustment required for mild to severe hepatic impairment (Child-Pugh A, B, or C).
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor hemoglobin closely.
Safety and efficacy not established in pediatric patients.
Children: 50 units/kg intravenously or subcutaneously three times weekly; adjust by 25 units/kg increments based on hemoglobin response. For anemia in chronic kidney disease: initial 50 units/kg three times weekly.
No specific dose adjustment recommended; use with caution due to limited data.
No specific dose adjustment in elderly; use same dosing principles as adults. Monitor for cardiovascular events and thromboembolism due to higher baseline risk.
Increased risk of thrombosis, including vascular access thrombosis, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Not approved for use in patients with active malignancy due to potential for tumor progression.
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence when targeting hemoglobin levels >11 g/d L. Use the lowest dose to avoid red blood cell transfusion. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Thrombotic events,Increased mortality in patients with cancer,Hypertension,Seizures,Gastric erosion and bleeding,Serious hepatotoxicity,Potential for tumor growth,Not for treatment of anemia due to other causes,Monitor hemoglobin levels
Increased mortality, serious cardiovascular events, and thromboembolic events when hemoglobin exceeds 11 g/d L; increased risk of tumor progression or recurrence in cancer patients; increased risk of seizures; pure red cell aplasia (PRCA) due to neutralizing antibodies; severe allergic reactions including anaphylaxis; hypertension; use with caution in patients with uncontrolled hypertension, history of seizures, or known hypersensitivity to albumin (human) or mammalian cell-derived products.
Uncontrolled hypertension,Active malignancy,History of thrombotic events (relative),Hypersensitivity to vadadustat or any component
Uncontrolled hypertension; known hypersensitivity to the drug or its components (including albumin human or mammalian cell-derived products); history of pure red cell aplasia (PRCA) following epoetin alfa therapy; use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
No significant food interactions. May be taken with or without food. Avoid grapefruit products as they may increase drug levels (moderate CYP3A4 interaction).
No specific food restrictions. Maintain adequate dietary iron intake (e.g., red meat, leafy greens) to support erythropoiesis. Avoid excessive alcohol which may interfere with treatment efficacy.
Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. There are no adequate human data on teratogenic risk. In animal studies, vadadustat caused embryofetal toxicity (reduced fetal weight, skeletal variations) at exposures similar to human exposure at the maximum recommended human dose. Based on mechanism of action, potential risks include impaired implantation and fetal development. First trimester: unknown risk; second and third trimesters: potential fetal hypoxia from altered erythropoiesis. Vafseo should be avoided during pregnancy unless clearly needed.
Pregnancy Category C. Animal studies have shown adverse effects (increased fetal mortality, growth retardation) at doses 2-3 times the human dose. No adequate well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: limited data, risk cannot be excluded. Second and third trimesters: may increase risk of hypertensive episodes and thrombotic events, which can compromise placental perfusion.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. The molecular weight (~340 Da) suggests potential excretion. Due to potential for serious adverse reactions (e.g., effects on erythropoiesis), breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. M/P ratio: unknown.
Recombinant erythropoietin is excreted in human milk in very low amounts; however, absorption from infant gastrointestinal tract is limited. The M/P ratio is unknown. Consider benefits of breastfeeding, mother's need for drug, and potential adverse effects on infant (e.g., polycythemia, hypertension). Caution advised.
No specific dose adjustments established for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, potentially requiring higher doses. However, lack of safety data precludes routine use; if necessary, use lowest effective dose and monitor hemoglobin closely to avoid excessive erythropoiesis. Consider avoiding use altogether.
There are no established dosing adjustments specific to pregnancy. Pharmacokinetic studies in pregnant women are lacking; however, physiologic changes (increased plasma volume, increased clearance) may require dose increases to maintain target hemoglobin levels. Individualize dosing to achieve hemoglobin levels within recommended range (10-12 g/d L) to avoid risks associated with high hemoglobin (hypertension, thrombosis) and low hemoglobin (poor fetal outcomes).
VAFSEO (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia due to chronic kidney disease (CKD). Monitor hemoglobin every 2 weeks during dose titration; target Hb ≤11 g/d L to reduce thrombotic risk. Avoid in patients with active malignancy due to potential tumor growth promotion. Drug interactions: reduce dose of VAFSEO when co-administered with strong CYP2C8 inhibitors (e.g., gemfibrozil); avoid with rifampin. Do not use erythropoiesis-stimulating agents concurrently. Assess iron stores and replete iron as needed.
Monitor hemoglobin weekly during initiation and dose titration; target Hb 10-12 g/d L to avoid cardiovascular events. Do not shake vial; use one dose per vial (preservative-free). Administer IV or SC; SC preferred for CKD patients. Iron deficiency must be corrected to ensure response; check ferritin and transferrin saturation. Hypertension is common; monitor BP. Hold dose if Hb > 13 g/d L or rapid rise > 1 g/d L in 2 weeks. Risk of pure red cell aplasia with SC use in CKD; switch to IV if suspected. Store refrigerated, do not freeze; protect from light. In cancer patients, use only for chemotherapy-induced anemia; not for patients receiving curative therapy.
Take VAFSEO exactly as prescribed, usually once daily with or without food.,Do not take VAFSEO if you have active cancer or are being treated for cancer.,Report signs of blood clots (e.g., leg swelling, chest pain, sudden shortness of breath) immediately.,Do not use other anemia medications (e.g., epoetin alfa) while on VAFSEO unless told by your doctor.,You will need regular blood tests to monitor hemoglobin and iron levels.,Take iron supplements if prescribed by your doctor; do not take additional iron without consulting your healthcare provider.,Inform all healthcare providers that you are taking VAFSEO.
This medicine helps your body make more red blood cells to treat anemia.,You will have regular blood tests to check your hemoglobin level and adjust the dose.,Report any symptoms of high blood pressure, such as severe headache, chest pain, or shortness of breath.,Do not miss any appointments for injections; keep a calendar or set reminders.,Store the medication in the refrigerator at 36°F to 46°F; do not freeze or shake.,Take iron supplements exactly as prescribed; iron is needed for this medicine to work.,Tell your doctor if you experience sudden anemia, loss of response, or severe tiredness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VAFSEO vs EPOGEN/PROCRIT, answered by our medical review team.
VAFSEO is a Erythropoiesis-Stimulating Agent that works by VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.. EPOGEN/PROCRIT is a Erythropoiesis-Stimulating Agent that works by Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VAFSEO and EPOGEN/PROCRIT depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VAFSEO is: Oral: 20 mg three times weekly for 24 weeks.. The standard adult dose of EPOGEN/PROCRIT is: 50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/d L).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VAFSEO and EPOGEN/PROCRIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VAFSEO is classified as Category C. Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. There are no adequate human data on teratogenic risk. In animal studies, vadadustat caused embryofet. EPOGEN/PROCRIT is classified as Category C. Pregnancy Category C. Animal studies have shown adverse effects (increased fetal mortality, growth retardation) at doses 2-3 times the human dose. No adequate well-controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.